SZD Stock Overview
Santen Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
Santen Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥8.85 |
| 52 Week High | JP¥9.70 |
| 52 Week Low | JP¥7.20 |
| Beta | 0.26 |
| 1 Month Change | -1.12% |
| 3 Month Change | -2.75% |
| 1 Year Change | 22.92% |
| 3 Year Change | -14.08% |
| 5 Year Change | -32.76% |
| Change since IPO | 127.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| SZD | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 2.3% | 3.2% | 1.7% |
| 1Y | 22.9% | -28.2% | 2.3% |
Return vs Industry: SZD exceeded the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: SZD exceeded the German Market which returned 2.3% over the past year.
Price Volatility
| SZD volatility | |
|---|---|
| SZD Average Weekly Movement | 4.5% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: SZD has not had significant price volatility in the past 3 months.
Volatility Over Time: SZD's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1890 | 4,144 | Takeshi Ito | www.santen.com |
Santen Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2a derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension. The company also offers sepetaprost, a prostaglandin analogue eye drop drug that is in phase 3 of clinical trials; and latanoprost, an ophthalmic emulsion of a prostaglandin F2a derivative which is filed for marketing approval for the treatment of glaucoma and ocular hypertension.
Santen Pharmaceutical Co., Ltd. Fundamentals Summary
| SZD fundamental statistics | |
|---|---|
| Market cap | €3.25b |
| Earnings (TTM) | €166.00m |
| Revenue (TTM) | €1.81b |
19.6x
P/E Ratio1.8x
P/S RatioIs SZD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SZD income statement (TTM) | |
|---|---|
| Revenue | JP¥302.08b |
| Cost of Revenue | JP¥119.10b |
| Gross Profit | JP¥182.98b |
| Other Expenses | JP¥155.27b |
| Earnings | JP¥27.71b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 09, 2024
| Earnings per share (EPS) | 76.15 |
| Gross Margin | 60.57% |
| Net Profit Margin | 9.17% |
| Debt/Equity Ratio | 0% |
How did SZD perform over the long term?
See historical performance and comparison